JP7518604B2 - タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法 - Google Patents

タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法 Download PDF

Info

Publication number
JP7518604B2
JP7518604B2 JP2018564844A JP2018564844A JP7518604B2 JP 7518604 B2 JP7518604 B2 JP 7518604B2 JP 2018564844 A JP2018564844 A JP 2018564844A JP 2018564844 A JP2018564844 A JP 2018564844A JP 7518604 B2 JP7518604 B2 JP 7518604B2
Authority
JP
Japan
Prior art keywords
sbt
dha
cells
tumor
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523226A5 (https=
JP2019523226A (ja
Inventor
イー． イーガン ジェイムス
オジマ イワオ
エム． アミジ マンソアー
イワーノヴナ ボチキーナ ガリーナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targagenix Inc
Original Assignee
Targagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc filed Critical Targagenix Inc
Publication of JP2019523226A publication Critical patent/JP2019523226A/ja
Publication of JP2019523226A5 publication Critical patent/JP2019523226A5/ja
Application granted granted Critical
Publication of JP7518604B2 publication Critical patent/JP7518604B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
JP2018564844A 2016-06-07 2017-06-07 タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法 Active JP7518604B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346755P 2016-06-07 2016-06-07
US62/346,755 2016-06-07
PCT/US2017/036330 WO2017214260A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Publications (3)

Publication Number Publication Date
JP2019523226A JP2019523226A (ja) 2019-08-22
JP2019523226A5 JP2019523226A5 (https=) 2020-07-27
JP7518604B2 true JP7518604B2 (ja) 2024-07-18

Family

ID=60578981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564844A Active JP7518604B2 (ja) 2016-06-07 2017-06-07 タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法

Country Status (9)

Country Link
US (3) US10206875B2 (https=)
EP (1) EP3463299A4 (https=)
JP (1) JP7518604B2 (https=)
CN (2) CN109562065A (https=)
AU (1) AU2017277497B2 (https=)
CA (1) CA3026412A1 (https=)
IL (1) IL263504A (https=)
MX (1) MX2018015112A (https=)
WO (1) WO2017214260A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214260A1 (en) * 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合
JP7610208B2 (ja) * 2019-03-22 2025-01-08 インテグレイテッド ナノセラピューティクス インコーポレイテッド 足場部分から調製した脂質結合体
EP4048310A4 (en) * 2019-10-25 2024-03-13 Amgen Inc. COMPOSITIONS AND METHODS FOR MINIMIZING PROTEIN LOSS AT LOW PROTEIN CONCENTRATIONS
EP4054550A4 (en) * 2019-11-05 2024-01-17 Luminus Biosciences Inc. NANOPARTICLES WITH PRODRUGS STABILIZED BY ALBUMIN FOR THE TREATMENT OF CANCER AND OTHER DISEASES
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114317398B (zh) * 2020-09-27 2024-03-01 中国科学院分子细胞科学卓越创新中心 Gli1和EpCAM基因共同标记的肝祖细胞群及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510648A (ja) 2003-10-30 2007-04-26 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク タキソイド−脂肪酸コンジュゲート及びその医薬組成物
US20070148194A1 (en) 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
US20140105829A1 (en) 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
JP5635504B2 (ja) * 2008-07-23 2014-12-03 ブハラット セルムズ アンド ヴァクシンズ リミテッド 安定した注射可能な水中油型ドセタキセルナノエマルション
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
SG11201609352TA (en) * 2014-06-19 2017-01-27 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
WO2015198350A1 (en) * 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
WO2017214260A1 (en) * 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007510648A (ja) 2003-10-30 2007-04-26 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク タキソイド−脂肪酸コンジュゲート及びその医薬組成物
US20070148194A1 (en) 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
US20140105829A1 (en) 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Ｂｉｏｏｒｇ． Ｍｅｄ． Ｃｈｅｍ．， ２０１４， Ｖｏｌ．２２， ｐｐ．５０７８－５０９０
Ｍｏｌｅｃｕｌａｒ Ｃａｎｃｅｒ，２０１０年，ｖｏｌ．９：１９２，ｐ．１－１２，ｈｔｔｐ：／／ｗｗｗ．ｍｏｌｅｃｕｌａｒ－ｃａｎｃｅｒ．ｃｏｍ／ｃｏｎｔｅｎｔ／９／１／１９２
Ｐｈａｒｍａｚｉｅ， ２０１１， Ｖｏｌ．６６， ｐｐ．４７９－４８３
ＳＥＩＴＺ Ｊｏｓｈｕａ ａｎｄ ＯＪＩＭＡ Ｉｗａｏ，Ｄｒｕｇ Ｃｏｎｊｕｇａｔｅｓ ｗｉｔｈ Ｐｏｌｙｕｎｓａｔｕｒａｔｅｄ Ｆａｔｔｙ Ａｃｉｄｓ，Ｄｒｕｇ Ｄｅｌｉｖｅｒｙ ｉｎ Ｏｎｃｏｌｏｇｙ，２０１２年，Ｃｈａｐｔｅｒ４１，ｐ．１３２３－１３５７

Also Published As

Publication number Publication date
US10206875B2 (en) 2019-02-19
USRE50096E1 (en) 2024-08-27
MX2018015112A (es) 2019-09-09
NZ748915A (en) 2024-09-27
CN109562065A (zh) 2019-04-02
AU2017277497B2 (en) 2023-05-04
JP2019523226A (ja) 2019-08-22
US20180028442A1 (en) 2018-02-01
EP3463299A1 (en) 2019-04-10
CA3026412A1 (en) 2017-12-14
IL263504A (en) 2019-01-31
AU2017277497A1 (en) 2018-12-20
WO2017214260A1 (en) 2017-12-14
EP3463299A4 (en) 2020-01-15
US20250009658A1 (en) 2025-01-09
CN116019768A (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
JP7518604B2 (ja) タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
Ahmad et al. Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth
Yang et al. Estrone-modified pH-sensitive glycol chitosan nanoparticles for drug delivery in breast cancer
Zhang et al. Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy
Chiang et al. Enhancement of cancer therapy efficacy by trastuzumab-conjugated and pH-sensitive nanocapsules with the simultaneous encapsulation of hydrophilic and hydrophobic compounds
Ravar et al. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation
Naguib et al. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation
Ye et al. Chitosan-coated doxorubicin nano-particles drug delivery system inhibits cell growth of liver cancer via p53/PRC1 pathway
Feng et al. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment
Guo et al. Aptamer-functionalized PEG–PLGA nanoparticles for enhanced anti-glioma drug delivery
Wang et al. Folate-decorated hybrid polymeric nanoparticles for chemically and physically combined paclitaxel loading and targeted delivery
Zhao et al. iTEP nanoparticle-delivered salinomycin displays an enhanced toxicity to cancer stem cells in orthotopic breast tumors
Li et al. Amifostine-conjugated pH-sensitive calcium phosphate-covered magnetic-amphiphilic gelatin nanoparticles for controlled intracellular dual drug release for dual-targeting in HER-2-overexpressing breast cancer
Xu et al. Enhancing the efficacy and safety of doxorubicin against hepatocellular carcinoma through a modular assembly approach: the combination of polymeric prodrug design, nanoparticle encapsulation, and cancer cell-specific drug targeting
KR102053065B1 (ko) 히알루론산 및 독소루비신을 이용한 pH 감응성 항암 엑소좀 조성물
WO2014036534A1 (en) Curcumin-er, a liposomal-plga sustained release nanocurcumin for minimizing qt prolongation for cancer therapy
Guo et al. Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy
CN102046011A (zh) 微管相互作用剂的脂质-油-水纳米乳递送系统
US12186428B2 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
Algandaby et al. Augmentation of anti-proliferative, pro-apoptotic and oxidant profiles induced by piceatannol in human breast carcinoma MCF-7 cells using zein nanostructures
Sorolla et al. Sensitizing basal-like breast cancer to chemotherapy using nanoparticles conjugated with interference peptide
Gupta et al. Folate receptor-targeted hybrid lipid-core nanocapsules for sequential delivery of doxorubicin and tanespimycin
Turkekul et al. Potent suppression of prostate cancer cell growth and eradication of cancer stem cells by CD44-targeted nanoliposome-quercetin nanoparticles
Myat et al. Antibody-decorated chitosan-iodoacetamide-coated nanocarriers for the potential delivery of doxorubicin to breast cancer cells
Chavoshi et al. Crocin-loaded liposomes sensitize MDA-MB 231 breast cancer cells to doxorubicin by inducing apoptosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220525

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220525

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220613

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220614

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220701

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240705

R150 Certificate of patent or registration of utility model

Ref document number: 7518604

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150